Vitae Pharmaceuticals, Inc. – Trademark Portfolio
Entity Type: 03
Vitae Pharmaceuticals, Inc. holds 12 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 6 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include VITAE, CONTOUR, and VITAE PHARMACEUTICALS. The owner is based in Fort Washington, PA.
502 West Office Center Drive
Fort Washington, PA 19034
Showing of trademarks Trademarks
Trademark Classifications
Vitae Pharmaceuticals, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Vitae Pharmaceuticals, Inc. have?
Vitae Pharmaceuticals, Inc. has 12 U.S. trademarks filed with the USPTO. Of these, 3 registered, 4 abandoned, 5 cancelled.
What trademark classes does Vitae Pharmaceuticals, Inc. file in?
Vitae Pharmaceuticals, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals). Class 42 covers scientific and technological services; industrial analysis and research services.
What are Vitae Pharmaceuticals, Inc.'s most well-known trademarks?
Vitae Pharmaceuticals, Inc.'s registered trademark portfolio includes well-known marks such as VITAE, CONTOUR, and VITAE PHARMACEUTICALS. These are among 3 currently registered trademarks in the portfolio.
What is Vitae Pharmaceuticals, Inc.'s trademark registration success rate?
Vitae Pharmaceuticals, Inc. has a 25% trademark registration rate, with 3 out of 12 resolved applications resulting in successful registration. Currently, 0 applications are pending review.